137 completed, 69 unknown, 66 recruiting, 29 active not recruiting. 81 Not applicable, 41 Phase 2, 26 Phase 3, 19 Phase 1, 14 Phase 4.
Follow Aortic Stenosis, Subvalvular: new trials by email Literature Review of Aortic Stenosis, Subvalvular trials Research Report on Aortic Stenosis, Subvalvular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aficamten and Patient-Reported Outcomes in Real-World nHCM receiving aficamten - Hypertrophic Cardiomyopathy (HCM) | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2027-06-01 | 2026-09-29 | |
| Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy Beta-Blocker Sequential Tapering and Discontinuation, Beta-Blocker Baseline Stable-Dose Maintenance - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not applicable | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 286 | 2026-12-01 | 2026-09-11 |
| NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices SESAME Procedure - Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction | Not applicable | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 200 | 2026-10-27 | 2026-10-22 |
| Human Experimental Models of Pain (HEMP) Placebo, Naproxen, Pregabalin - Acute Pain | Not applicable | Not yet recruiting | National Center for Complementary and Integrative Health (NCCIH) | 25 | 2026-10-27 | 2026-10-22 |
| Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy QG101-23-0 enteric coated capsule (60/120/240/360 mg BID), QG101-23-0 enteric coated capsule (120/240/360/480mg BID) - Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM) | Phase 2 | Not yet recruiting | Amckaus PTY LTD. | 56 | 2026-10-01 | 2026-06-30 |
| Echocardiographic Perspectives on Transient Mitral Regurgitation After Septal Myectomy Hypertrophic Cardiomyopathy | Not yet recruiting | University Health Network, Toronto | 150 | 2026-10-01 | 2026-10-14 | |
| Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy Coronary sinus reducer, Placebo procedure - Hypertrophic Cardiomyopathy | Not applicable | Not yet recruiting | Imperial College London | 50 | 2026-10-01 | 2026-10-08 |
| Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not yet recruiting | Bristol-Myers Squibb | 800 | 2026-09-30 | 2026-09-29 | |
| Individualized Exercise Training in Hypertrophic Cardiomyopathy Exercise Intervention, Physical Activity Handout - Hypertrophic Cardiomyopathy (HCM) | Not applicable | Not yet recruiting | Oregon Health and Science University | 60 | 2026-09-15 | 2026-09-23 |
| BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy BHB-1893, Metoprolol - Cardiomyopathy, Hypertrophic Obstructive | Phase 3 | Recruiting | Braveheart Bio, Inc. | 210 | 2026-09-02 | 2026-10-02 |
| IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten Cardiomyopathy, Hypertrophic Obstructive | Not yet recruiting | French Cardiology Society | 150 | 2026-09-01 | 2026-07-21 | |
| Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 4 | Not yet recruiting | Second Affiliated Hospital of Nanchang University | 115 | 2026-09-01 | 2026-09-08 |
| HCMR Re-Imaging Study None - observational study - Hypertrophic Cardiomyopathy (HCM) | Recruiting | Christopher Kramer | 314 | 2026-07-27 | 2026-10-16 | |
| A Real-world HCM-cohort Trial Standard of care - Hypertrophic Cardiomyopathy (HCM) | Not yet recruiting | Xijing Hospital | 3000 | 2026-06-30 | 2026-06-10 | |
| Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy LX2006, Usual Care - Friedreich Ataxia, Cardiomyopathy, Secondary | Phase 2 | Recruiting | Lexeo Therapeutics | 26 | 2026-06-25 | 2026-09-02 |
| A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population No interventions were applied to the patients. - Hypertrophic Cardiomyopathy (HCM) | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 3000 | 2026-06-01 | 2026-09-15 | |
| Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy Observational study, no new intervention offered - Hypertrophic Cardiomyopathy (HCM) | Not yet recruiting | University of Manchester | 140 | 2026-06-01 | 2026-02-13 | |
| Radiomics Analysis of CMR Imaging for Arrhythmic Risk Prediction in Hypertrophic Cardiomyopathy, With Longitudinal Risk Reassessment After Mavacamten Therapy in Obstructive Patients Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitors | Active not recruiting | Centro Cardiologico Monzino | 2000 | 2026-06-01 | 2026-07-10 | |
| Mechanisms of Atrial Pathoelectrophysiology in HCM Hypertrophic Cardiomyopathy (HCM), Atrial Fibrillation (AF) | Recruiting | Guy's and St Thomas' NHS Foundation Trust | 40 | 2026-05-26 | 2026-09-11 | |
| Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy Aficamten - Hypertrophic Cardiomyopathy (HCM) | Phase 4 | Recruiting | Oregon Health and Science University | 40 | 2026-05-05 | 2026-05-20 |
Showing 20 of 354. Sign in to see all of them.
Cardiomyopathy, Hypertrophic (352) · Cardiomyopathy, Dilated (38) · Cardiomyopathies (29) · Heart Failure (20) · Arrhythmogenic Right Ventricular Dysplasia (15) · Cardiomyopathy, Restrictive (13) · Hypertrophy, Left Ventricular (13) · Cardiovascular Diseases (12) · Death, Sudden, Cardiac (11) · Heart Diseases (11) · Coronary Artery Disease (10) · Fabry Disease (9) · Ventricular Outflow Obstruction, Left (9) · Amyloid Neuropathies, Familial (8) · Atrial Fibrillation (8)
Aortic Valve Disease (353) · Heart Valve Diseases (353) · Aortic Valve Stenosis (349) · Heart Diseases (343) · Cardiovascular Diseases (342) · Cardiomyopathies (324) · Pathological Conditions, Signs and Symptoms (78) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (72) · Genetic Diseases, Inborn (62) · Cardiomegaly (50) · Pathologic Processes (46) · Laminopathies (37) · Vascular Diseases (34) · Pathological Conditions, Anatomical (26)
MYK-461 (37) · Exercise (6) · Echocardiography (5) · Metoprolol (5) · Ethanol (4) · Perhexiline (4) · Blood Specimen Collection (3) · Losartan (3) · sacubitril and valsartan sodium hydrate drug combination (3) · Adrenergic beta-Antagonists (2) · Anti-Arrhythmia Agents (2) · Bisoprolol (2) · Cardiac Resynchronization Therapy (2) · Defibrillators, Implantable (2) · Diltiazem (2)
Bristol-Myers Squibb (25) · National Heart, Lung, and Blood Institute (NHLBI) (24) · Xijing Hospital (11) · China National Center for Cardiovascular Diseases (9) · Chinese Academy of Medical Sciences, Fuwai Hospital (7) · Mayo Clinic (6) · Meshalkin Research Institute of Pathology of Circulation (6) · Shandong Suncadia Medicine Co., Ltd. (6) · Cytokinetics (5) · Imperial College London (5) · Second Affiliated Hospital, Zhejiang University, School of Medicine (5) · Assistance Publique - Hôpitaux de Paris (4) · Barts & The London NHS Trust (4) · French Cardiology Society (4) · MyoKardia, Inc. (4)
United States (119) · China (69) · United Kingdom (48) · France (31) · Italy (28) · Germany (26) · Canada (23) · Spain (19) · Netherlands (14) · Poland (13) · Denmark (11) · Australia (10) · Czechia (9) · Israel (9) · Portugal (9)
Aleksandr V Bogachev-Prokophiev, PhD (2) · Barry Greenberg, MD (2) · James Ware (2) · Jeffrey Geske, MD (2) · Jonathan C Fox, MD, PhD (2) · Joseph Rossano, MD (2) · Milind Desai, MD (2) · Robert J Lederman, M.D. (2) · Stefan Neubauer, MD (2) · Steven E Lipshultz, MD (2) · Xiang Wei, M.D. (2)
PMID 42636950, PMID 24621999, PMID 25533774, PMID 28306757, PMID 28912187, PMID 31642911, PMID 32871100, PMID 34081217, PMID 36652223, PMID 39217450, PMID 39302117, PMID 42624353, PMID 42669063, PMID 12106931, PMID 12196333, PMID 12493162, PMID 12957437, PMID 14668703, PMID 14670830, PMID 14736546, PMID 14990846, PMID 15234411, PMID 15914483, PMID 16432071, PMID 16507234, PMID 16507235, PMID 16539843, PMID 16562568, PMID 16702455, PMID 17131076, PMID 17239718, PMID 17268122, PMID 17572266, PMID 17582361, PMID 18164940, PMID 18403758, PMID 19074594, PMID 20659762, PMID 20837938, PMID 20921440, PMID 22075468, PMID 22932717, PMID 23713888, PMID 24361242, PMID 24414062, PMID 24645908, PMID 24674997, PMID 25176015, PMID 25387993, PMID 25533966
2023 (4), 2019 (2), 1RC1LM010526 (1), 2025 (1), K23HL004444 (1), K23HL078901 (1), K23HL136902 (1), P50HL112349 (1), R01AG059613 (1), R01AG081582 (1), R01HL042467 (1), R01HL072705 (1), R01HL111459 (1), R01HL125918 (1), R01HL128743 (1)